Breaking News, Collaborations & Alliances

Ribobay Pharma Integrates Cytiva’s FlexFactory Platform for Oligonucleotides

Will rapidly expand its oligo CRDMO business, producing several hundred kilograms of pharmaceutical oligo per year.

Author Image

By: Charlie Sternberg

Associate Editor

Ribobay Pharma, a Chinese biopharmaceutical contract research, development, and manufacturing organization (CRDMO) and a spin-off company of General Biol (Anhui) Co., Ltd, has tapped Cytvia’s first FlexFactory platform for oligonucleotide (oligo) manufacturing to provide cGMP-level oligo CRDMO services to the world.   It is scheduled to commence manufacturing in June and expects to produce several hundred kilograms of pharmaceutical oligo per year, bringing increased reliability, speed, and ef...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters